报价延迟最少15分钟:2025/12/19 13:51 EST
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
2.18 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-2.21/-1.52
|
|
企业价值
157.01M
|
| 资产负债 |
|
每股账面净值
1.54
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, isa subclass monoclonal antibody that selectively targets amyloid-beta oligomers. |
